by Prakash Achaary | Jan 24, 2022 | Blog
In September 2021, the Food and Drug Administration (FDA) released its Benefit-Risk Assessment Guidance as part of the Prescription Drug User Fee Amendments (PDUFA) VI Implementation Plan which covers 2018 through 2022. PDUFA VI focuses on integrating patient...
by Prakash Achaary | Jan 10, 2022 | Blog
Antisense oligonucleotide (ASO) drug products target a specific sense mRNA to modulate gene expression in living cells and have been used successfully to treat diseases where the pathogenic mutation has been identified. For patients with an...
by Prakash Achaary | Dec 22, 2021 | Blog
2021 brought more challenges and opportunities than ever before. From the starts and stops of opening workplaces, schools and economies to managing an overflowing email inbox, it can be challenging to keep up with all the information you need. So, we rounded up...
by Prakash Achaary | Dec 16, 2021 | News
CANTON, Mich. (12/15/2021) – MMS Holdings Inc., an award-winning, data-focused CRO, announced a restructuring of their consulting services with the launch of a Project Advisory Services Unit to meet the needs of many small to mid-sized organizations in immediate,...
by Prakash Achaary | Dec 8, 2021 | News
CANTON, Mich. (12/8/2021) – MMS Holdings, a data-focused CRO, is pleased to announce its selection as Best Contract Research Organization – Specialist Providers in the 2021 Scrip Awards. The Scrip Awards, held annually by London-based Informa Pharma...